Usual Blood Pressure and Risk of New-Onset Diabetes Evidence From 4.1 Million Adults and a Meta-Analysis of Prospective Studies by Emdin, Connor A. et al.
J O U R N A L O F T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y V O L . 6 6 , N O . 1 4 , 2 0 1 5
ª 2 0 1 5 B Y T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y F O U N D A T I O N I S S N 0 7 3 5 - 1 0 9 7 / $ 3 6 . 0 0
P U B L I S H E D B Y E L S E V I E R I N C . h t t p : / / d x . d o i . o r g / 1 0 . 1 0 1 6 / j . j a c c . 2 0 1 5 . 0 7 . 0 5 9Usual Blood Pressure and
Risk of New-Onset Diabetes
Evidence From 4.1 Million Adults and a
Meta-Analysis of Prospective StudiesConnor A. Emdin, HBSC,* Simon G. Anderson, PHD,*y Mark Woodward, PHD,*z Kazem Rahimi, DM, MSC*xABSTRACTFro
Ins
He
Un
fun
the
su
Ins
Me
Ox
an
Lis
MaBACKGROUND Reliable quantiﬁcation of the association between blood pressure (BP) and risk of type 2 diabetes is lacking.
OBJECTIVES This study sought to determine the association between usual BP and risk of diabetes, overall and by
participant characteristics.
METHODS A cohort of 4.1 million adults, free of diabetes and cardiovascular disease, was identiﬁed using validated
linked electronic health records. Analyses were complemented by a meta-analysis of prospective studies that reported
relative risks of new-onset diabetes per unit of systolic blood pressure (SBP).
RESULTS Among the overall cohort, 20 mm Hg higher SBP and 10 mm Hg higher diastolic BP were associated with a
58% and a 52% higher risk of new-onset diabetes (hazard ratio: 1.58; 95% conﬁdence interval [CI]: 1.56 to 1.59; and
hazard ratio: 1.52; 95% conﬁdence interval: 1.51 to 1.54), respectively. There was no evidence of a nadir to a baseline BP
of 110/70 mm Hg. The strength of the association per 20 mm Hg higher SBP declined with age and with increasing body
mass index. Estimates were similar even after excluding individuals prescribed antihypertensive or lipid-lowering ther-
apies. Systematic review identiﬁed 30 studies with 285,664 participants and 17,388 incident diabetes events. The pooled
relative risk of diabetes for a 20 mm Hg higher usual SBP across these studies was 1.77 (1.53 to 2.05).
CONCLUSIONS People with elevated BP are at increased risk of diabetes. The strength of the association declined with
increasing body mass index and age. Further research should determine if the observed risk is modiﬁable.
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AB BR E V I A T I O N S
AND ACRONYM S
BMI = body mass index
BNF = British National
Formulary
BP = blood pressure
CPRD = Clinical Research
Practice Datalink
DBP = diastolic blood pressure
HR = hazard ratio
RAS = renin-angiotensin
system
SBP = systolic blood pressure
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1553Although hypertension has long been recognized
as an independent risk factor for fatal and nonfatal
vascular events (4), the relationship between blood
pressure (BP) and risk of new-onset diabetes is less
clear. Elevated BP is associated with chronic inﬂam-
mation (5) and endothelial dysfunction (6), both of
which appear to be mediators of diabetes risk (7,8).
There is, therefore, a biological rationale to suspect
that elevated BP may cause new-onset diabetes.
However, among 30 cohort studies that have reported
the association of BP and diabetes, 12 concluded that
no such association is apparent, whereas the others
reported a considerably variable strength of associa-
tion (Online Table 1). Moreover, even the largest
previous cohorts have had limited power to investi-
gate whether any observed positive association be-
tween BP and diabetes varied signiﬁcantly by
important patient features (9).SEE PAGE 1563A detailed understanding of BP as a potential
risk factor for diabetes will help us better understand
and communicate risks with patients and can lead
to more targeted prevention and management. We
therefore undertook both an analysis of 4.1 million
individuals free from diabetes and cardiovascular
disease in a contemporary U.K. primary care popula-
tion and a meta-analysis of existing prospective
studies to reliably determine the association between
BP and diabetes.
METHODS
We used prospectively collected records from the
U.K. Clinical Practice Research Datalink (CPRD) to
assemble a cohort of 4.1 million patients free from
vascular disease and diabetes. An electronic health
record system, covering approximately 9% of the U.K.
population, CPRD has been validated for epidemio-
logical research into a range of diagnoses (10,11).
Eligible patients were additionally linked to Hospital
Episode Statistics for secondary care/hospitalization
data and to cause-speciﬁc mortality data.
PARTICIPANTS, EXPOSURES, AND OUTCOMES. Patients
were eligible for inclusion if they had a BP measure-
ment performed between January 1, 1990, and
January 1, 2013, and were between 30 and 90 years
(inclusive) of age at the time of measurement. Addi-
tionally, patients needed to have their age recorded
and be registered at a general practice for at least
1 year. To reduce measurement error to which
single BP measurements are prone and to diminish
the impact of short-term ﬂuctuations in BP on
observed associations, the initial measurement wastransformed into “usual blood pressure” to
adjust for regression dilution bias and the
calculated usual BP was used as the exposure.
All patients with pre-existing vascular dis-
ease (ischemic heart disease, cerebrovascular
disease, heart failure, peripheral vascular
disease, or renal disease) and diabetes (either
type 1 or type 2) were excluded. Baseline
covariates (body mass index [BMI], total
cholesterol, high-density lipoprotein choles-
terol, and smoking status) were deﬁned as
the closest measurement within 2 years of the
baseline BP measurement for that covariate.
The primary outcome was a diagnosis of
type 2 diabetes, deﬁned as either clinical diagnosis of
type 2 diabetes or diabetes unspeciﬁed (because 90%
of diabetes cases are type 2 [12]) or prescription of
insulin/antidiabetic drugs, as deﬁned in the British
National Formulary (BNF) chapters 6.1.1 and 6.1.2.
Participants were censored at the earliest occurrence
of the primary outcome, transfer out of practice,
death, or last collection date of practice.
STATISTICAL ANALYSES. Cox models, stratiﬁed by
practice to account for clustering at the practice level,
were used to determine hazard ratios (HRs) for BP
categories for each outcome. The proportional hazards
assumption was tested by plotting Schoenfeld re-
siduals. The primary analysis was adjusted for age,
sex, BMI, smoking status, baseline antihypertensive
use (BNF chapters 2.2.1, 2.2.3, 2.2.4, 2.4, 2.5, 2.6.2), and
baseline lipid-lowering agent use (BNF chapter 2.12),
although further adjustment was undertaken in sen-
sitivity analyses. Blood pressure was analyzed both
as a continuous variable (per 20/10 mm Hg higher BP)
and as a categorical variable. Usual systolic blood
pressure (SBP) was deﬁned by category: #95 mm Hg,
>195 mm Hg, and increments of 10 mm Hg for every-
thing in between (e.g., 96 to 105 mm Hg, 106 to 115
mm Hg, and so on). Usual diastolic blood pressure
(DBP) also was deﬁned by the measured diastolic BP
categories:#65mmHg,>115 mmHg, and for 10mmHg
increments for everything in between (e.g., 66 to 75
mm Hg, and so on). BP categories were entered
simultaneously into the Cox model (separate models
for SBPs and DBPs) and estimated simultaneously.
Floating absolute risks were used to display HRs for BP
categories because ﬂoating absolute risks do not
require the selection of a baseline group for display of
standard errors (13). The variance of each estimate
approximates the variance in the underlying category.
Multiple imputation using chained equations was
used to impute missing covariates; 5 imputations
were generated.
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1554Measurement error and short-term ﬂuctuations in
BP will bias any potential association of BP with an
outcome of interest to the null (an effect termed
regression dilution bias). Because we were interested
in the etiological association of BP with risk of new-
onset diabetes, free of regression dilution bias, we
used similar methods to the Emerging Risk Factors
Collaboration to adjust for regression dilution bias
(14–17). That is, we regressed serial BP measurements
within the median follow-up on the baseline BP
measurement, but used generalized estimating
equations rather than linear models to account for
multiple serial BP measurements among participants.
Regression dilution ratios were calculated as the
inverse of the coefﬁcient relating the serial mea-
surements to the baseline measurement. Regression
dilution ratios of 2.1 for SBP and 2.5 for DBP were
estimated. Continuous HRs for measured BP (i.e., per
20/10 mm Hg) were then multiplied by these ratios to
estimate the association for usual BP. For example, if
an HR for baseline SBP of 1.5 was calculated, the
HR for usual SBP was calculated as: exp (2.1$log
[1.5]) ¼ 2.3. For displaying HRs of BP as a categorical
variable (i.e., 120 to 130 mm Hg measured SBP),
measured BP was “shrunk” toward the overall mean
BP by the calculated regression dilution ratios, as
performed previously (18). For instance, if the overall
mean of the baseline SBP measurements was 130
mm Hg and the mean of a speciﬁc BP category was
140, the mean usual BP of that category was calculated
as: (140 mm Hg  130 mm Hg)/2.1) þ 130 ¼ 135 mm Hg.
Six sensitivity analyses were conducted. First,
models were further adjusted for total and high-
density lipoprotein cholesterol. Second, models
were further adjusted for year of the initial BP mea-
surement, as a categorical variable (1990 to 1994, 1995
to 1999, 2000 to 2004, 2005 to 2009, and 2010 to 2013)
to control for potential cohort effects. Third and
fourth, to minimize the risk of reverse causality,
individuals with an event in the ﬁrst 2 years of follow-
up and an event in the fourth year of follow-up were
excluded. Fifth, individuals prescribed antihyper-
tensive medication or lipid-lowering drugs at baseline
or during follow-up were excluded because statins
and classes of antihypertensive agents have been
associated with an increased risk of diabetes (19,20).
Sixth, diagnosis of diabetes was deﬁned as an explicit
diagnosis of type 2 diabetes (that is, excluding in-
dividuals who were only diagnosed with unspeciﬁed
diabetes or prescribed antidiabetic medicine without
a concomitant diagnosis of type 2 diabetes).
META-ANALYSIS. A systematic search strategy was
designed and conducted by an experienced researchlibrarian to identify previous studies of the associa-
tion between BP and risk of new-onset diabetes. The
strategy included MeSH terms and synonyms for the
terms blood pressure, incident, and diabetes. MED-
LINE was searched for articles published between
1966 and January 2015, with no language restrictions
applied. Prospective observational studies, including
observational analyses of randomized trials, were
eligible for inclusion if they: 1) had at least 1 year of
follow-up; 2) were reported a risk per unit of SBP that
could be standardized to 20 mm Hg higher SBP; and 3)
were adjusted for, at minimum, sex, age, and BMI.
The latter was required for adjustment given that BMI
is a strong risk factor for diabetes (21) and is associ-
ated with elevated BP (22). Studies conducted in
populations immediately after renal transplantation
and studies that examined gestational diabetes were
excluded. Measures of relative risks (e.g., HRs and
odds ratios), difference in BP, study population,
number of incident diabetes events, and degree of
adjustment were extracted in duplicate. Because no
study adjusted for regression dilution bias, we pooled
relative risks standardized to 20 mm Hg higher usual
SBP by multiplying the reported relative risks per 20
mm Hg higher measured SBP by our regression dilu-
tion coefﬁcient. Random effects meta-analysis was
used due to the presence of high heterogeneity
(I2 >50%). Test for interaction between subgroups
was performed using Cochran’s Q test.
One study reported a relative risk of new-onset
diabetes per 10 mm Hg higher DBP; this was
assumed to correspond to a relative risk per 20 mm Hg
higher SBP. Five studies reported relative risks of
new diabetes comparing one-ﬁfth of BP relative to
another ﬁfth but did not explicitly report a difference
in SBP between ﬁfths (9,21,23–25). A normal approxi-
mation was therefore assumed to determine the
approximate difference in BP between ﬁfths to allow
for standardization per 20 mm Hg higher SBP. These
5 studies were excluded in a sensitivity analysis.
Analyses were performed using R, version 3.0
(R Foundation for Statistical Computing, Vienna,
Austria).
RESULTS
A total of 4,694,120 individuals in the CPRD cohort
had at least 1 BP measurement with at least 1 year of
follow-up and were between 30 and 90 years of age,
inclusive. After excluding 195,623 patients with
existing diabetes and an additional 366,359 patients
who had pre-existing cardiovascular disease, we
identiﬁed a cohort of 4,132,138 individuals (Online
Figure 1).
TABLE 1 Baseline Characteristics
Baseline Usual BP*
Overall
(n ¼ 4,132,138)
<127 mm Hg
(n ¼ 1,474,462)
127-136 mm Hg
(n ¼ 1,541,802)
>136 mm Hg
(n ¼ 1,115,874)
Follow-up, yrs 6.4 (2.7-11.1) 6.7 (3.0-11.0) 7.3 (3.4-11.2) 6.8 (3.0-11.1)
Age at baseline, yrs 39 (33-48) 46 (37-57) 59 (48-70) 46 (36-59)
Women 983,263 (66.7) 771,273 (50.0) 555,732 (49.8) 2,310,268 (55.9)
BMI, kg/m2† 24.3 (21.9-27.3) 26.2 (23.5-29.6) 27.3 (24.4-30.9) 25.7 (23.0-29.2)
Smoking status†
Current smoker 369,263 (30.1) 356,553 (28.4) 218,099 (25.2) 943,915 (28.2)
Never smoker 671,681 (54.7) 677,155 (53.9) 469,610 (54.2) 1,818,446 (54.3)
Former smoker 186,428 (15.2) 223,496 (17.8) 179,436 (20.7) 589,360 (17.6)
Cholesterol (mmol/l)†
Total 5.2 (4.6-6.0) 5.5 (4.8-6.2) 5.7 (5.0-6.4) 5.5 (4.8-6.3)
HDL 1.4 (1.1-1.7) 1.4 (1.2-1.7) 1.3 (1.1-1.6) 1.4 (1.1-1.7)
Most deprived ﬁfth 275,902 (18.7) 286,718 (18.6) 217,095 (19.5) 779,715 (18.9)
Medication usage
Antihypertensive at baseline 53,248 (3.6) 124,596 (8.1) 212,781 (19.1) 390,625 (9.5)
Antihypertensive during follow-up 191,575 (13.0) 381,426 (24.7) 581,966 (52.2) 1,154,967 (28.0)
Lipid-lowering at baseline 10,037 (0.7) 24,215 (1.6) 24,604 (2.2) 58,856 (1.4)
Lipid-lowering during follow-up 98,305 (6.7) 214,055 (13.9) 280,189 (25.1) 592,549 (14.3)
Values are median (interquartile range) or n (%). *Baseline usual BP categories of <127 mm Hg, 127 to 136 mm Hg, and >136 mm Hg correspond to baseline measured BP
categories of <121 mm Hg, 121 to 140 mm Hg, and >140 mm Hg. †Proportion of variables missing: BMI (31.2%), smoking status (18.9%), total cholesterol (74.6%), HDL
cholesterol (81.3%). No other variables contained missing values.
BMI ¼ body mass index; BP ¼ blood pressure; HDL ¼ high-density lipoprotein.
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1555At baseline, women comprised 2,310,268 (55.9%) of
the participants (Table 1). The median age was 46
years (interquartile range: 36 to 59), whereas the
median BMI, before imputation, was 25.7 kg/m2
(interquartile range: 23.0 to 29.2 kg/m2). During a
median follow-up of 6.8 years, 186,698 new-onset
diabetes events were observed.
ASSOCIATIONS OF USUAL BP WITH NEW-ONSET
DIABETES. When analyzed using Kaplan-Meier
curves, individuals with elevated BP had greater
incidence of new diabetes during follow-up (Central
Illustration). When analyzed using Cox proportional
hazards models, adjustment for age, sex, and BMI
attenuated diabetes risk (unadjusted HR: 2.60; 95%
CI: 2.58 to 2.62 per 20 mm Hg higher SBP; adjusted
HR: 1.58; 95% CI: 1.57 to 1.60 per 20 mm Hg higher
SBP), although additional adjustment for smoking,
antihypertensive therapy use, and lipid-lowering
therapy use had little effect on estimates (Central
Illustration). Usual SBP was continuously related to
risk of new-onset diabetes (Figure 1). Although there
was no evidence of a nadir down to a usual SBP level
of 110 mm Hg, a ﬂattening of the curve was observed
below approximately 120 mm Hg. The association was
strongest among individuals with a normal to mildly
elevated BP, with an additional ﬂattening of the curve
above 150 mm Hg. Usual DBP was also continuously
related to risk of new diabetes, with no evidence of a
nadir or plateau in the range from 70 to 100 mm Hg.Overall, a 20 mm Hg higher SBP and a 10 mm Hg
higher DBP were associated with a 58% increase
(HR: 1.58; 95% CI: 1.56 to 1.59) and 52% increase
(HR: 1.52; 95% CI: 1.51 to 1.54) in risk of newly diag-
nosed diabetes, respectively.
The proportional association between SBP and
newly diagnosed diabetes differed by baseline BMI
and age (Figures 2 and 3). A 20 mm Hg higher SBP was
associated with a greater proportional increase in the
risk of diabetes among individuals with a BMI #25
kg/m2 (HR: 1.89; 95% CI: 1.84 to 1.94) than among
individuals with a BMI >35 kg/m2 (HR: 1.19; 95% CI:
1.16 to 1.22; p for interaction < 0.0001). However, the
higher baseline absolute risk at BMI >35 kg/m2
resulted in larger absolute risk increases in diabetes
per 20 mm Hg higher SBP in this BMI range (Figure 2).
A 10 mm Hg higher usual DBP was associated with a
73% higher risk of diabetes among individuals with a
BMI <20 kg/m2 (HR: 1.73; 95% CI: 1.68 to 1.78),
whereas it was associated with a 19% higher risk
among individuals with a BMI >35 kg/m2 (HR: 1.19;
CI: 1.16 to 1.22; p for interaction: < 0.0001) (Figure 3).
The relative risk of new-onset diabetes per 20
mm Hg higher usual SBP declined with increasing age,
from an HR of 2.00 (95% CI: 1.96 to 2.04) at 30 to 50
years of age to an HR of 1.14 (95% CI: 1.11 to 1.17) at
71 to 90 years of age (Figures 2 and 3). However,
because of the increasing absolute risk of diabetes
with older age, the absolute risk differences per
CENTRAL ILLUSTRATION Elevated Blood Pressure and Risk of New-Onset Diabetes
Emdin, C.A. et al. J Am Coll Cardiol. 2015; 66(14):1552–62.
(Top) Kaplan-Meier curves illustrating time to incident diabetes by (A) usual systolic blood pressure categories and (B) usual diastolic blood pressure
categories. No adjustments were applied. (Bottom) Hazard ratios per 20 mm Hg higher systolic blood pressure and 10 mm Hg higher diastolic blood
pressure for new-onset diabetes, with progressive adjustment for age, sex, BMI, smoking and baseline antihypertensive use and baseline lipid-lowering
drug use. BMI ¼ body mass index; CI ¼ conﬁdence interval; DBP ¼ diastolic blood pressure; HR ¼ hazard ratio; SBP ¼ systolic blood pressure.
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FIGURE 1 Adjusted HR for Diabetes by Systolic Blood Pressure and Diastolic Blood Pressure
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Hazard ratios for diabetes rose with increasing blood pressure. Adjustments were made for age, body mass index, smoking status, sex, and
blood pressure category (plotted). CIs are displayed as ﬂoating absolute risks. Area of each square is proportional to the inverse variance of the
estimate. Usual SBP categories were deﬁned by the measured SBP categories: <95 mm Hg, >195 mm Hg, and increments of 10 mm Hg for
everything in between (e.g., 95 to 105 mm Hg, 106 to 115 mm Hg, and so on); usual DBP categories were deﬁned by the measured DBP
categories: <65 mm Hg, >115 mm Hg, and intervening increments of 10 mm Hg (66 to 75 mm Hg, and so on). Blood pressure categories were
entered simultaneously into the Cox model (separate models for SBP and DBP) and estimated simultaneously. Floating absolute risks were used
to display all hazard ratios (13). The variance of each estimate approximates the variance in the underlying category. CI ¼ conﬁdence interval.
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155720 mm Hg usual SBP were similar across the different
age groups, despite the declining relative risks. Risk
of diabetes per 10 mm Hg higher DBP similarly
declined with increasing age, from an HR of 1.89 (95%
CI: 1.86 to 1.92) to 1.01 (95% CI: 0.98 to 1.04) (Figure 3).
When SBP and DBP was included in the same
model, both were positively related to risk of
diabetes with similar strengths of association; 20
mm Hg usual SBP was associated with an HR of 1.42
(95% CI: 1.40 to 1.44) and 10 mm Hg usual DBP was
associated with an HR of 1.51 (95% CI: 1.49 to 1.54).
When all individuals prescribed BP-lowering
drugs or statins at baseline or during follow-up
were excluded in a sensitivity analysis, estimates
were similar (Online Figure 2). Further adjustment
for total and high-density lipoprotein cholesterol,
socioeconomic status, and period of initial BP mea-
surement also had little effect on estimated associa-
tions between SBP and DBP and risk of new-onset
diabetes (Online Figures 3 and 4). Exclusion ofindividuals diagnosed with diabetes within the ﬁrst 2
years and within the ﬁrst 4 years of follow-up also had
little effect on associations (Online Figures 5 and 6).
Estimates also did not change materially when dia-
betes was restricted to explicit diagnosis of type 2
diabetes (Online Figure 7).
META-ANALYSIS. Thirty prospective observational
studies were identiﬁed (Online Figure 8), with
285,664 participants and 17,388 incident diabetes
events. Pooled random effects meta-analysis showed
that each 20 mm Hg higher usual SBP from prior
cohort studies was associated with a 77% higher risk
of new diabetes (relative risk: 1.77; 95% CI: 1.53 to
2.05) (Figure 4). A test for interaction with our esti-
mate of 58% higher risk of diabetes per 20 mm Hg
usual SBP was not signiﬁcant (p ¼ 0.14). The overall
pooled coefﬁcient, including our and previous cohort
studies, was 76% per 20 mm Hg higher usual SBP
(relative risk: 1.76; 95% CI: 1.56 to 1.97). Estimates
were similar when 5 studies that used a normal
FIGURE 2 Adjusted Hazard Ratios for Diabetes by SBP and BMI or Age
110 120 130 140 150 160 170
Usual Systolic Blood Pressure (mm Hg)
110 120 130 140 150 160 170
Usual Systolic Blood Pressure (mm Hg)
> 35
31-35
26-30
≤ 25
71-90
51-70
30-50
1
2
4
8
16
32
Ha
za
rd
 R
at
io
 (9
5%
 C
I)
1
2
4
8
Ha
za
rd
 R
at
io
 (9
5%
 C
I)
BMI AgeA B
Adjustments were for smoking status, sex, and the interaction between SBP as a categorical variable and (A) BMI category (plotted) and (B) age
category (plotted). BMI ¼ body mass index; other abbreviations as in Figure 1.
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ciated with the provided relative risk were excluded
(Online Figure 9).
DISCUSSION
In a cohort of people without known previous vas-
cular disease and with more than 180,000 presenta-
tions of newly diagnosed diabetes, both SBP and DBP
were found to continuously relate to risk of new-onset
diabetes, with no evidence of a nadir down to 110/70
mm Hg. The strengths of associations varied substan-
tially between different subpopulations. In particular,
relative risks per 20 mm Hg higher SBP and 10 mm Hg
higher DBP declined with increasing age and with
increasing BMI. Nevertheless, because of higher
absolute risk of diabetes at older age and with higher
BMI, a 20 mm Hg difference in SBP and 10 mm Hg dif-
ference in DBP were still associated with substantial
absolute risk differences in old age and overweight.
Previous observational analyses have been con-
ﬂicted on the relationship between elevated BP and
diabetes risk (Online Table 1). For example, in an
observational analysis of the Losartan Intervention
For Endpoint study, 20 mm Hg higher SBP wasassociated with a 39% higher risk of new diabetes (HR:
1.39; 95% CI: 1.25 to 1.56) (26); in the Women’s Health
Study, hypertensive individuals had twice the risk of
developing diabetes relative to those with SBP be-
tween 120 and 129 mm Hg (HR: 2.03; 95% CI: 1.77 to
2.32) (9). Additionally, higher on-treatment SBP was
associated with a higher risk of new-onset diabetes
in the International Verapamil SR-Trandolapril study
(27). However, in a prospective cohort study of risk
factors for diabetes in 7,097 men, no association was
observed between baseline BP and diabetes risk after
adjustment for clinical and demographic covariates
(21). These qualitatively and quantitatively discrepant
ﬁndings are most likely because of the limited power
of individual studies to reliably measure modest
risk associations, as supported by our systematic re-
view, which shows that the pooled estimate across
these studies support a modest association between
elevated SBP and risk of diabetes (Figure 4).
Our results support the hypothesis that elevated
BP is associated with increased risk of diabetes.
Indeed, our estimate of a 58% increase in risk of new-
onset diabetes per 20 mm Hg higher usual SBP did not
differ signiﬁcantly from a pooled estimate. In addi-
tion to conﬁrming the overall effects from previous
FIGURE 3 Association Between Blood Pressure and Diabetes per Baseline Variables
Subgroup No. ofdiabetes
HR per 20 mm Hg
higher SBP HR 95%    CI Subgroup
No. of
diabetes
HR per 10 mm Hg
higher DBP HR
Usual SBP
0–130
131–140
141–150
>150
35621
71071
50242
29764
Test for interaction: p<0.0001
Sex
Female
Male
89252
97446
Test for interaction: p<0.0001
BMI
0–25
26–30
31–35
>35
29821
67049
51232
38596
Test for interaction: p<0.0001
Age
30–50
51–70
71–90
68762
92146
25790
Test for interaction: p<0.0001
Overall 186698
1 2.5
1.91 [1.78; 2.04]
2.13 [2.00; 2.27]
1.46 [1.35; 1.58]
1.13 [1.09; 1.17]
1.54 [1.52; 1.56]
1.61 [1.59; 1.64]
1.89 [1.84; 1.94]
1.64 [1.62; 1.67]
1.39 [1.36; 1.41]
1.19 [1.16; 1.22]
2.00 [1.96; 2.04]
1.49 [1.47; 1.51]
1.14 [1.11; 1.17]
1.58 [1.56; 1.59]
Usual DBP
0–70
71–80
81–90
>90
407
78219
97673
10399
Test for interaction: p<0.0001
Sex
Female
Male
89252
97446
Test for interaction: p<0.0001
BMI
0–25
26–30
31–35
>35
29821
67049
51232
38596
Test for interaction: p<0.0001
Age
30–50
51–70
71–90
68762
92146
25790
Test for interaction: p<0.0001
Overall 186698
1.42 [0.93; 2.18]
1.62 [1.57; 1.68]
1.54 [1.49; 1.59]
1.14 [1.05; 1.23]
1.47 [1.44; 1.49]
1.57 [1.54; 1.59]
1.73 [1.68; 1.78]
1.54 [1.51; 1.57]
1.34 [1.31; 1.37]
1.19 [1.16; 1.22]
1.89 [1.86; 1.92]
1.36 [1.34; 1.39]
1.01 [0.98; 1.04]
1.52 [1.51; 1.54]
1 2.5
95%     CI
Adjustments were for age, sex, BMI, baseline antihypertensive use, and baseline lipid-lowering therapy use. For subgroups of age, adjustment was also for age
category and the interaction between SBP and age category (plotted). For subgroups of sex, adjustment was also for the interaction between sex and SBP (plotted).
For subgroups of BMI, adjustments were also for BMI category and the interaction between SBP and BMI category (plotted). Area of each square is proportional to the
inverse variance of the estimate. In various subgroups (usual SBP or DBP, sex, BMI, and age), proportional associations were seen between newly diagnosed diabetes
and a 20 mm Hg higher SBP or 10 mm Hg higher DBP. A greater proportional risk was seen with the lowest BMI category versus the highest in both blood pressure
groups; similarly, increasing age was associated with decreasing risk. Abbreviations as in Figures 1 and 2.
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1559reports, our study’s large sample size extends pre-
vious reports by investigating the differences in as-
sociations by key population characteristics, such as
age, sex, and BMI (Central Illustration). The im-
portance of these more detailed subpopulation ana-
lyses is highlighted by the large differences in the
relative risks by patient characteristics in our cohort.
For example, in contrast with a previous report, in
which no interaction by BMI (on the basis of 1,672
events) was observed, we found that a 20 mm Hg
higher SBP was associated with an 89% higher risk
among individuals with a BMI #25 kg/m2, but a 19%
higher risk among people with a BMI >35 kg/m2.
It is unclear whether the observed association
between BP and diabetes is causal. The Nateglinide
and Valsartan in Impaired Glucose Tolerance Out-
comes Research trial, which supports a causalrelationship, randomized 9,306 patients to valsartan
or placebo and established a 2.8 mmHg SBP difference
between arms. Incidence of diabetes in the valsartan
arm was signiﬁcantly reduced (HR: 0.86; 95% CI: 0.80
to 0.92) (28). However, a network meta-analysis of
randomized trials of antihypertensive medication
observed that only angiotensin-converting enzyme
inhibitors and angiotensin receptor blockers reduced
diabetes risk (20), suggesting it is renin-angiotensin
system (RAS) activation that is causally related to risk
of new-onset diabetes and not BP per se. However, the
lack of a reduction in new diabetes observed for di-
uretics, beta-blockers, and calcium-channel blockers
may be due to off-target effects for these therapies
rather than a lack of a relationship between BP and
diabetes risk (29). Previous analyses have suggested
that a causal relationship between mediators of
FIGURE 4 Association Between Higher Usual SBP and Diabetes Risk
Study Diabetes /
Participants
Relative Risk
(95% Confidence Interval)
Previous
Norberg Men
Golden
Norberg Women
Chihaoui Men
Mykkanen
Mullican
Chihaoui Women
Stolk Men
Kramer
Li
Stolk Women
Conen
Fukui
Yasuno
Lee
Sawada
Hatami Family History
Ohlson
Njolstad Women
Hatami No Family History
Meisinger Women
Njolstad Men
Niklason
Kumari Men
Kumari Women
Wei African–American
Bjornholt
Meisinger Men
Burchfiel
Nagaya Women
Wei White
Perry
Barzilay
Hayashi
Okin
Nagaya Men
Stahl
Weycker
Gupta
101 / 291
77 / 1152
76 / 222
32 / 271
60 / 805
213 / 2767
45 / 430
33 / 1780
85 / 1125
125 / 465
32 / 2029
599 / 15982
262 / 4304
97 / 2685
246 / 14054
274 / 4187
93 / 835
47 / 766
75 / 5556
127 / 2193
85 / 3114
87 / 6098
NA / 5033
242 / 5807
119 / 2579
372 / 2252
143 / 1947
128 / 3052
334 / 5863
224 / 8368
657 / 8341
194 / 7097
534 / 6486
600 / 7594
520 / 7485
869 / 16828
509 / 7333
7706 / 104368
1366 / 14120
17388 / 285664Random effects model
Heterogeneity: I-squared=83.9%, p<0.0001
Current
Emdin 186698 / 4132138
Random effects model 204086 / 4417802
Heterogeneity: I-squared=85.8%, p<0.0001
0.8 1 1.25 4
1.53 [0.40; 5.84]
4.47 [1.56; 12.84]
1.53 [0.53; 4.38]
1.37 [0.55; 3.43]
1.89 [0.79; 4.53]
2.31 [0.99; 5.40]
1.19 [0.52; 2.72]
2.87 [1.29; 6.37]
3.56 [1.63; 7.77]
2.21 [1.04; 4.70]
1.39 [0.66; 2.93]
4.89 [2.42; 9.87]
1.41 [0.70; 2.83]
1.42 [0.74; 2.72]
1.27 [0.67; 2.41]
3.42 [1.82; 6.42]
1.25 [0.68; 2.32]
2.33 [1.35; 4.01]
1.45 [0.89; 2.36]
1.86 [1.15; 3.01]
1.50 [0.94; 2.40]
1.40 [0.91; 2.14]
1.47 [0.96; 2.24]
1.53 [1.00; 2.33]
1.53 [1.00; 2.33]
0.88 [0.58; 1.34]
1.02 [0.68; 1.55]
2.03 [1.36; 3.01]
1.54 [1.07; 2.22]
3.01 [2.14; 4.25]
1.45 [1.04; 2.01]
1.25 [0.91; 1.72]
1.53 [1.14; 2.06]
2.03 [1.60; 2.56]
2.07 [1.65; 2.61]
2.11 [1.77; 2.53]
1.50 [1.31; 1.72]
3.83 [3.37; 4.35]
1.33 [1.18; 1.50]
1.77 [1.53; 2.05]
1.58 [1.56; 1.59]
1.76 [1.56; 1.97]
A meta-analysis showed that each 20 mm Hg higher usual SBP from previous cohort studies was associated with a 77% higher risk of new
diabetes. Study refers to ﬁrst author of study. Abbreviations as in Figures 1 and 2.
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PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Elevated blood
pressure is associated with the risk of developing diabetes, and
there is no nadir in the normotensive range.
TRANSLATIONAL OUTLOOK: Randomized trials are needed
to establish causation and to determine whether lowering blood
pressure, particularly by administration of inhibitors of the renin-
angiotensin-aldosterone system, will reduce the risk of devel-
oping diabetes.
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1561chronic inﬂammation, speciﬁcally interleukin-6, and
incident diabetes may exist (7,30). Chronic inﬂamma-
tion characterizes both obesity (31) and elevated BP (5),
risk factors for diabetes, and is reduced by RAS inhi-
bition (32). Thus, chronic inﬂammation may mediate,
in part, the relationship between both risk factors
(obesity and hypertension) and incident diabetes.
Alternatively, endothelial dysfunction may link ele-
vated BP and diabetes (8). An individual patient data
meta-analysis, such as the Blood Pressure Lowering
Treatment Trialists’ Collaboration, would be ideally
suited to examine whether BP lowering, independent
of RAS inhibition, reduces the risk of new diabetes.
Assuming causality, this analysis suggests that
individual- and population-based efforts to lower BP
may also lower the incidence of diabetes. Because
RAS inhibition has been demonstrated to reduce the
incidence of new diabetes in randomized trials, pre-
scription of angiotensin-converting enzyme in-
hibitors and angiotensin receptor blockers has the
most reliable evidence base for reducing the inci-
dence of diabetes at an individual level. Although
we observed a declining proportional association
between BP and risk of diabetes with increasing BMI,
the greater absolute risk of diabetes at higher BMI
would support targeting individuals with high BMI
for BP lowering to prevent diabetes. Population-
based efforts to lower BP, for example, by reducing
alcohol consumption through policy interventions or
by promoting exercise, may also lead to reductions in
the incidence of diabetes. However, further research
is needed to examine the causality of the described
associations and determine whether BP lowering
without renin-angiotensin inhibition would reduce
risk of new-onset diabetes.
STUDY STRENGTHS AND LIMITATIONS. This anal-
ysis has several strengths, including its large size,
encompassing more than 4.1 million individuals and
180,000 incident diabetes events, and contemporary
nature. One potential limitation is that we used
routinely collected electronic health records for our
analysis. Although this approach has recently been
used to examine the relationship between type 2 dia-
betes and cardiovascular risk, it is possible that some of
our type 2 diabetes eventsmay have beenmisclassiﬁed(e.g., metabolic syndrome but not type 2 diabetes).
However, a previous study suggested that physician-
diagnosed type 2 diabetes events in CPRD are highly
reliable (33). Furthermore, we supplemented our
analysis with a meta-analysis of prospective obser-
vational studies within 285,664 individuals and
17,388 incident diabetes events. This complementary
approach increased our study’s reliability, allowing us
to ﬁrst validate our estimate against previous studies
and then examine the relationship betweenBP and risk
of diabetes in various subpopulations. Our estimate of
an overall 58% increase per 20mmHg higher usual SBP
was consistent with our meta-analysis of previous
observational studies that largely used adjudicated
diabetes events and was consistent in 6 sensitivity
analyses, including an analysis of explicit diagnoses of
type 2 diabetes (rather than unspeciﬁed diabetes).
CONCLUSIONS
A 20 mm Hg higher SBP was associated with a 58%
higher risk of new-onset diabetes, whereas a 10
mm Hg higher DBP was associated with a 52% higher
risk of developing diabetes. The strength of the as-
sociation declined with increasing BMI and age.
Further investigation is needed to determine whether
this association is causal.
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